Vaccines and Biotechnology city
VBC was founded on the belief that manufacturing biological medicines, such as vaccines, is vital to the future of healthcare. We recognize the urgent need to localize vaccine production across Egypt, Africa, and the Middle East.
The COVID-19 pandemic underscored the importance of having the capability to develop and produce vaccines locally. In response, this project was initiated under the directive of the Egyptian Presidency to strengthen national security and promote self-sufficiency.
VBC is a biopharmaceutical company committed to the discovery, development, and commercialization of vaccines and biotechnological products, with a primary focus on safeguarding against biological threats and emergencies.
Through our diverse portfolio, we protect both people and animals by delivering safe, reliable, and effective vaccines. Backed by robust research and a team of dedicated experts, we are advancing preventive healthcare and prioritizing initiatives that raise community health standards.
By focusing on prevention, we strive to reduce the burden of disease, improve quality of life, and foster healthier populations.
VBC is building a continental center for vaccine production, guaranteeing availability and aligning with the African Union’s vision of producing 60% of vaccines locally by 2040.
Strategically located in Egypt, we are well-positioned to provide safe, reliable, and affordable vaccines for Africa and the Middle East, thereby contributing to health security and regional self-sufficiency.
We, as VBC, are committed to supporting the Sustainable Development Goals (SDGs), which serve as a blueprint for a more equitable and sustainable future.
Our initiatives are aligned with key SDGs, particularly: Sustainable Cities and Communities — Through awareness campaigns, emergency preparedness initiatives, and efforts to promote health equity, we contribute to building healthier, more resilient communities.
We aim to make a meaningful and lasting impact on one health by integrating these goals into our business practices, decision-making processes, and corporate culture.
The architectural design process typically includes conceptual design, schematic design, design development, construction documents, and construction administration.
The architectural design process typically includes conceptual design, schematic design, design development, construction documents, and construction administration.
The architectural design process typically includes conceptual design, schematic design, design development, construction documents, and construction administration.
The architectural design process typically includes conceptual design, schematic design, design development, construction documents, and construction administration.
Professor of Infectious Diseases at Cairo University with over 35 years of global experience in leading pharmaceutical corporations, including Pfizer, MSD, and Boehringer Ingelheim.
He is the CEO, Founder, and Shareholder of Vaccines and Biotechnology City (VBC), a private-public partnership with MEVAC/UVAC and NSPO, dedicated to localizing vaccine production and advancing health security in Africa and the Middle East.
Dr. Magdy is also the Chairman and Founder of MEVAC, one of Egypt’s largest animal vaccine exporters to over 40 countries, and a member of the Egyptian Medical Industries Export Council. He additionally founded UVAC for Human Vaccines and UBM for Pharma & Veterinary Products, representing several international companies in Egypt and the region.
He has led the development of classical, recombinant, and mRNA vaccines, driving innovation in line with the One Health vision to protect humans, animals, and the environment.
President & CEO of Kemin Industries, a global nutritional ingredients company operating in 90+ countries with over $910 million annual revenue and products reaching 4 billion people daily.
Since 1993, he has led Kemin’s growth—quadrupling its size to more than 2,800 employees and securing over 500 patents worldwide. Kemin pioneered the purification of lutein, a breakthrough supporting eye health, which is consumed by over 60 million people daily.
Recognized among the Top 100 CEO Leaders in STEM, he has been a strong advocate for science education, serving twice as Board Chair of the Science Center of Iowa.
He holds a Ph.D. in Biochemistry and Biophysics from Washington State University, 10 patents, and numerous published research studies.
Board Member at VBC and MEVAC for Vaccines since 2006, where he contributes to shaping the company’s strategic direction, overseeing financial performance, and developing governance and compliance policies.
A distinguished finance and business executive with over 30 years of expertise in accounting, financial management, and executive leadership within multinational organizations. He is recognized for driving sustainable growth, strengthening corporate governance, and ensuring sound financial performance, alongside deep expertise in strategic planning, risk management, and building partnerships to support long-term organizational success.
He also serves as the Chief Executive Officer and Co-Founder of United Biomed since 1997, where he leads overall strategic direction, operations, and financial performance, with a strong focus on continuous expansion and strengthening partnerships.
Established in 1979 by Presidential Decree No. 32, NSPO plays a vital role in supporting Egypt’s national development plans through its diverse industrial and service activities.
Its mission is to achieve relative self-sufficiency for the Country while supplying surplus production to the local market, easing the state’s economic burden, and contributing to major national projects.
By combining the efficiency of private sector practices with the strength of state-owned enterprises, NSPO has become a pillar of national economic growth and a key driver of sustainable development in Egypt.
CEO of MEVAC and Board Member of VBC, with over 15 years of experience in marketing, technical, regulatory, and sales management of veterinary vaccines and products across Egypt and the MENA region.
He successfully led a team of 470 employees across research, quality, production, sales, and marketing, with exports to more than 42 countries in Africa, Asia, Latin America, and Eastern Europe. He is recognized for achieving market penetration and building sustainable growth strategies.
Dr. El Kady holds an MBA in Strategic Management & Marketing from the German University in Cairo, along with international certifications in supply chain management and marketing.
English
